EIM
BPMC

Essex Investment Management’s Blueprint Medicines BPMC Stock Holding History

Essex Investment Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,291
Closed -$4.65M – 303
2025
Q2 		$4.65M Sell
36,291
-5,234
-13% -$544K 0.85% 31
2025
Q1 		$3.68M Sell
41,525
-4,211
-9% -$411K 0.77% 40
2024
Q4 		$3.99M Buy
45,736
+10,275
+29% +$941K 0.72% 42
2024
Q3 		$3.28M Buy
+35,461
New +$3.52M 0.57% 67
2018
Q4 		– Sell
-19,137
Closed -$1.49M – 487
2018
Q3 		$1.49M Buy
19,137
+12,924
+208% +$898K 0.18% 174
2018
Q2 		$394K Buy
+6,213
New +$494K 0.05% 305

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Essex Investment Management's BPMC Position: Q3 2025 in Review

Essex Investment Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 36,291 shares — an estimated $4.65M sold.

Essex Investment Management first reported a position in BPMC in Q2 2018 and held it in 6 quarters. The position peaked at $4.65M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Essex Investment Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Essex Investment Management sold 36,291 Blueprint Medicines shares in Q3 2025, an estimated $4.65M.
  • Essex Investment Management first reported a position in Blueprint Medicines in Q2 2018 and held it in 6 quarters.
  • Essex Investment Management's Blueprint Medicines position peaked at $4.65M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Essex Investment Management's 13F filing for Q3 2025, filed 6 Nov 2025.